Oncofetal protein IMP3: A useful diagnostic biomarker for leiomyosarcoma

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1567-1572

  Cornejo, Kristine ^a   Shi, Min ^a   Jiang, Zhong ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Diagnostic biomarker; IMP3; Leiomyoma; Leiomyoma variants; Leiomyosarcoma; Soft tissue tumor

Indexed keywords

ONCOFETAL ANTIGEN; ONCOFETAL PROTEIN IMP3; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SMOOTH MUSCLE; UTERUS MYOMA; UTERUS TUMOR;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; NEOPLASM GRADING; RNA-BINDING PROTEINS; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84866488198     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.12.020     Document Type: Article

References (31)

1. J.R. Toro, L.B. Travis, H.J. Wu, K. Zhu, C.D. Fletcher, and Devesa SS Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases Int J Cancer 119 2006 2922 2930 (Pubitemid 44846246)
2. C.H. Lee, D.A. Turbin, and Y.C. Sung A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors Mod Pathol 22 2009 1519 1531
3. G. Toledo, and E. Oliva Smooth muscle tumors of the uterus: a practical approach Arch Pathol Lab Med 132 2008 595 605 (Pubitemid 351489613)
4. E. D'Angelo, and J. Prat Uterine sarcomas: a review Gynecol Oncol 116 2010 131 139
5. C.J. O'Neill, H.A. McBride, L.E. Connolly, and W.G. McCluggage Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential Histopathology 50 2007 851 858 (Pubitemid 46850073)
6. P.P. Ip, K.Y. Tse, and K.F. Tam Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy Adv Anat Pathol 17 2010 91 112
7. E. D'Angelo, L.G. Spagnoli, and J. Prat Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system Hum Pathol 40 2009 1571 1585
8. M.R. Nucci, and B.J. Quade Uterine mesenchymal tumors C.P. Crum, M.R. Nucci, K.R. Lee, 2nd ed. Diagnostic gynecologic and obstetric pathology 2011 Elsevier Saunders Philadelphia, PA 582 639
9. H. Gokaslan, L. Turkeri, and Z.N. Kavak Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors Gynecol Obstet Invest 59 2005 36 40 (Pubitemid 40082295)
10. K.L. Hall, M.G. Teneriello, and R.R. Taylor Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas Gynecol Oncol 65 1997 330 335 (Pubitemid 27216950)
11. K.R. Mittal, F. Chen, and J.J. Wei Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas Mod Pathol 22 2009 1303 1311
12. P.P. Ip, A.N. Cheung, and P.B. Clement Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases Am J Surg Pathol 33 2009 992 1005
13. L. Chen, and B. Yang Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors Int J Gynecol Pathol 27 2008 326 332
14. F. Mueller-Pillasch, B. Pohl, and M. Wilda Expression of the highly conserved RNA binding protein KOC in embryogenesis Mech Dev 88 1999 95 99 (Pubitemid 29467415)
15. F.C. Nielsen, J. Nielsen, and J. Christiansen A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking Scand J Clin Lab Invest Suppl 234 2001 93 99 (Pubitemid 33043632)
16. Z. Jiang, P.G. Chu, and B.A. Woda Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study Lancet Oncol 7 2006 556 564 (Pubitemid 43923666)
17. R.K. Yantiss, B.A. Woda, and G.R. Fanger KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas Am J Surg Pathol 29 2005 188 195 (Pubitemid 40170636)
18. Z. Jiang, C.M. Lohse, and P.G. Chu Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas Cancer 112 2008 2676 2682 (Pubitemid 351969211)
19. Z. Jiang, P.G. Chu, and B.A. Woda Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas Clin Cancer Res 14 2008 5579 5584
20. N.E. Hoffmann, Y. Sheinin, and C.M. Lohse External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma Cancer 112 2008 1471 1479 (Pubitemid 351441159)
21. D. Lu, P. Vohra, P.G. Chu, B. Woda, K.L. Rock, and Z. Jiang An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia Am J Surg Pathol 33 2009 521 525
22. W. Zheng, X. Yi, and O. Fadare The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma Am J Surg Pathol 32 2008 304 315 (Pubitemid 351172146)
23. T. Wang, L. Fan, and Y. Watanabe L523S, an RNA-binding protein as a potential therapeutic target for lung cancer Br J Cancer 88 2003 887 894 (Pubitemid 36520876)
24. L. Sitnikova, G. Mendese, and Q. Liu IMP3 predicts aggressive superficial urothelial carcinoma of the bladder Clin Cancer Res 14 2008 1701 1706 (Pubitemid 351469454)
25. M. Shi, A.E. Fraire, and P. Chu Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation Am J Surg Pathol 35 2011 878 882
26. B. Liao, Y. Hu, D.J. Herrick, and G. Brewer The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells J Biol Chem 280 2005 18517 18524 (Pubitemid 41389102)
27. J. Vikesaa, T.V. Hansen, and L. Jonson RNA-binding IMPs promote cell adhesion and invadopodia formation EMBO J 25 2006 1456 1468
28. M.R. Hendrickson, F.A. Tavassoli, R.L. Kempson, W.G. McCluggage, U. Haller, and R.A. Kubik-Huch Mesenchymal tumours and related lesions F.A. Tavassoli, P. Devilee, World Health Organization classification of tumours: international agency for research on cancer. pathology and genetics of tumours of the breast and female genital organs 2003 IARC Press Lyon, France 233 244
29. H.L. Evans, and J. Shipley Leiomyosarcoma C.D.M. Fletcher, K. Krishnan Unni, F. Mertens, World Health Organization classification of tumours: international agency for research on cancer. Pathology and genetics of tumours of soft tissue and Bone 2002 IARC Press Lyon, France 131 134
30. C.D.M. Fletcher, A. Rydholm, S. Singer, M. Sundaram, and J.M. Coindre Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading C.D.M. Fletcher, K. Krishnan Unni, F. Mertens, World Health Organization classification of tumours: international agency for research on cancer. Pathology and genetics of tumours of soft tissue and bone 2002 IARC Press Lyon, France 12 18
31. C. Li, V. Zota, and B.A. Woda Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations Mod Pathol 20 2007 1263 1268 (Pubitemid 350126850)